Hypersensitivity pneumonitis in Covid-19: mortality, risk factors, and clinical outcomes from a 30-case observational study

This is a preview and has not been published.

Hypersensitivity pneumonitis in Covid-19: mortality, risk factors, and clinical outcomes from a 30-case observational study

Authors

  • Elif Yelda Ozgun Niksarlioglu Health Science University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Istanbul, Turkey https://orcid.org/0000-0002-6119-6540
  • Mehmet Atilla Uysal Health Science University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Istanbul, Turkey https://orcid.org/0000-0002-0430-498X
  • Ekrem Cengiz Seyhan Health Science University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Istanbul, Turkey https://orcid.org/0000-0001-6639-2797
  • Murat Kıyık Health Science University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Istanbul, Turkey https://orcid.org/0000-0001-8737-1418
  • Erdoğan Çetinkaya Health Science University, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Chest Diseases, Istanbul, Turkey https://orcid.org/0000-0002-0891-0020

Keywords:

covid-19, hypersensitivity pneumonitis, mortality, risk factors, covid pneumonia, hospitalized patients, observational study, steroid treatment

Abstract

.

References

Dessie ZG, Zewotir T. Mortality related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis 2021;21:855 doi: 10.1186/s12879-021-06536

15. Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with intersitital lung disease. Am J Respir Crit Care Med. 2020;202(12):1656-1665. doi:10.1164/rccm.202007-2794OC.

Lee H, Hayoung C, Yang B, et al. Interstitial lung disease increases the susceptibility and severity of COVID-19. Eur Respir J 2021;58:2004125. doi: 10.1183/13993003.04125-2020.

Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81. doi: 10.1016/S2213-2600(20)30079-5.

Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-1316. doi: 10.1001/jama.2020.17021.

Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19-Preliminary report. N Engl J Med. 2021; 384: 693-704. doi:10.1056/NEJMoa2021436.

Downloads

How to Cite

1.
Ozgun Niksarlioglu EY, Uysal MA, Seyhan EC, Kıyık M, Çetinkaya E. Hypersensitivity pneumonitis in Covid-19: mortality, risk factors, and clinical outcomes from a 30-case observational study. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. [cited 2025 Mar. 7];42(1):16163. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/16163

Issue

Vol. 42 No. 1 (2025)

Section

Letter to Editor
DOI: https://doi.org/10.36141/svdld.v42i1.16163

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Ozgun Niksarlioglu EY, Uysal MA, Seyhan EC, Kıyık M, Çetinkaya E. Hypersensitivity pneumonitis in Covid-19: mortality, risk factors, and clinical outcomes from a 30-case observational study. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. [cited 2025 Mar. 7];42(1):16163. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/16163
Crossref
Scopus
Google Scholar
Europe PMC